AXV 101
Alternative Names: AXV-101Latest Information Update: 17 May 2024
At a glance
- Originator Axovia Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Bardet-Biedl Syndrome
Most Recent Events
- 10 May 2024 Axovia Therapeutics plans a first in Human trial for Bardet-Biedl Syndrome in first half of 2025 (Axovia Therapeutics pipeline, April 2024)
- 10 May 2024 Axovia Therapeutics plans a development program for Obesity in 2026
- 19 Sep 2023 AXV 101 receives Orphan Drug status for Bardet-Biedl Syndrome in USA